Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044413 | 0.82 | PTGS2 (0.53) | HSD17B10HTTLMNAPTGS2KDM4E | |
| SCHEMBL9465765 | 0.81 | PTGS2 (0.38) | HSD17B10HTTLMNAPTGS2MMP2 | |
| SCHEMBL14074048 | 0.81 | PTGS2 (0.38) | HTTLMNAPTGS2HRH3MMP2 | |
| SCHEMBL10044416 | 0.79 | PTGS2 (0.43) | HSD17B10LMNAPTGS2 | |
| SCHEMBL11590582 | 0.78 | MEN1 (0.38) | GAAHTTLMNAPTGS2HRH3 | |
| SCHEMBL24803365 | 0.78 | KDM4E (0.39) | PTGS2KDM4E | |
| SCHEMBL25746400 | 0.78 | MPO (0.41) | HSD17B10LMNAPTGS2MEN1KMT2A | |
| SCHEMBL10196841 | 0.78 | GAA (0.40) | GAAHSD17B10HTTLMNAPTGS2 | |
| SCHEMBL13896321 | 0.77 | MEN1 (0.37) | GAAHTTLMNAPTGS2HRH3 | |
| SCHEMBL14446918 | 0.77 | LMNA (0.59) | GAAHSD17B10HTTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-09-11 | — | — | US | disclosed |
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-09-11 | — | — | US | disclosed |
| EP-1840126-A1 | 2-(CYCLIC AMINOCARBONYL)INDOLINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-10-03 | — | — | EP | disclosed |
| CN-1093124-C | Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' | GLAXO GROUP LTD (GB) | 2002-10-23 | — | — | CN | disclosed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| CN-1218460-A | Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' | GLAXO GROUP LTD (GB) | 1999-06-02 | — | — | CN | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | CYP11B2, CYP11B1, GRIN2A | GAA 3365/4885HSD17B10 683/4885HTT 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.